The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Hormones & growth

Tesa + Ipa Blend

Tesamorelin (strong GHRH analog) plus ipamorelin (GHRP) in one vial, a GH stack focused on visceral fat.

2 min read 13 sources

To the product To the calculator
Tesa + Ipa Blend vial with white powder and the black TPD label on a white podium with a glowing ring, next to two molecule models of blue spheres: a large tangled one and a smaller chain-like one with rings
Ipamorelin only in phase 2 · not approvedLab tested in the shop

Summary

At a glance

Sources checked on 26 Oct 2026

Belly fat with tesamorelin
-15.2 %

phase 3 at 26 weeks in HIV, placebo +5.0%2

Tesamorelin half-life
8 minutes

after a single dose under the skin in healthy adults9

Ipamorelin half-life
2 hours

after one infusion in healthy men6

On the ready-made blend
0 trials

no registered trial with both together, as of 26 Oct 202610

  • The blend combines tesamorelin, a stabilised GHRH analogue, with ipamorelin, a ghrelin mimetic of five building blocks. Both trigger growth hormone release, via two different receptors.125
  • That both paths amplify each other was shown in a study of 18 healthy men with GHRH and an older ghrelin mimetic. It has not been studied with tesamorelin and ipamorelin together.810
  • In two phase 3 trials tesamorelin lowered visceral belly fat by 15.2 and 10.9 percent in 26 weeks. In animal studies ipamorelin did not raise ACTH and cortisol more than GHRH.235
  • Ipamorelin was tested in phase 2 after bowel surgery and was well tolerated, but did not significantly shorten the time to the first meal.7
  • Only tesamorelin is approved, in the US since 2010 for belly fat in HIV. There is no study on the blend. Everything here is the state of research, not a recommendation.121310
Profile

Updated May 2026

Class
GH stack

GHRH analog + GHRP

Use
Subcutaneous

in mg

Contents
Tesamorelin

6mg, + ipamorelin (11mg)

WADA
Banned

peptide hormones

Sizes
17 mg

1 size in the shop

Contents 15 sections
  1. At a glance
  2. What is the Tesa + Ipa Blend?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. Side effects
  11. Storage
  12. Related compounds
  13. FAQ
  14. Glossary
  15. Sources

What is the Tesa + Ipa Blend?

This blend combines tesamorelin, a particularly strong GHRH analog, with ipamorelin, a selective GHRP, in a 17mg vial (6mg tesa + 11mg ipa). You also find both individually in the lexicon. Tesamorelin is clinically known mainly for reducing visceral belly fat.

Comparison

One path or two

The blend next to the single compounds and the blend with CJC-1295, as stated in the TPD lexicon. Tap a card to open its entry.

Blend, two paths Tesa + Ipa Blend GHRH Ghrelin 2 of 2 receptors
GHRH analogue, approved Tesamorelin GHRH Ghrelin 1 of 2 receptors Ghrelin mimetic Ipamorelin GHRH Ghrelin 1 of 2 receptors Blend with CJC-1295 CP10 (CJC + IPA) GHRH Ghrelin 2 of 2 receptors

Simplified: that two paths amplify each other has only been shown with older peptides in healthy adults, not with this blend. 8

How it works

As with the CP10 stack, two systems of the GH axis interlock: tesamorelin at the GHRH receptor, ipamorelin at the ghrelin receptor. Together this gives a strong GH pulse. The difference from CP10: tesamorelin is seen as the more potent GHRH analog with a particular focus on visceral fat.

The individual mechanisms are in the lexicon entries for tesamorelin and ipamorelin.

Where it acts

Where the two components act

Tap a point or a card. Colour = receptor, grey = observed in studies of the single compound.

  1. Pituitary

    Two paths to growth hormone release, stronger together than alone (healthy men, older peptides)8

    GHRHGhrelin
  2. Belly fat

    Tesamorelin: visceral fat -15.2 percent in 26 weeks, subcutaneous fat barely changed2

    Observed in trials
  3. Liver

    Tesamorelin: 35 percent with normal liver fat after 12 months, placebo 4 percent4

    Observed in trials
  4. Gut

    Ipamorelin after bowel surgery: first meal tolerated earlier, difference not significant7

    Observed in trials

Targets in the ChEMBL database12

Compound CHEMBL1237026 (Tesamorelin), CHEMBL58547 (Ipamorelin): two recorded mechanisms, type of action on each card.

GHRH receptor (tesamorelin)
Gene
GHRHR
UniProt
Q02643
ChEMBL
CHEMBL2032
Action
Agonist, direct binding according to ChEMBL
Ghrelin receptor GHS-R1a (ipamorelin)
Gene
GHSR
UniProt
Q92847
ChEMBL
CHEMBL4616
Action
Agonist according to studies, no mechanism recorded in ChEMBL
Glass gland on a stalk sends a beam of light with blue molecule models towards a cluster of translucent cells that lights up where it hits
Two signals to the pituitary. Symbolic image.

What you need

Supplies

2 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

Tesa + Ipa Blend vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid

  1. Blend vial

    The blend vial (lyophilized powder, both compounds).

    In the shop

  2. Water and supplies

    Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

    In the shop

Reconstitution

Use the peptide calculator. The values refer to the total amount (17mg). A 17mg vial with 1.7ml water gives 10mg total per ml: 3.1mg is then 31 units on the U-100 syringe, 1.5mg is 15 units. Just add the water to the vial and let it dissolve.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 17 mg + 1.7 ml = 10 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

Subcutaneous, ideally fasted. Because of the tesamorelin share it is classically injected into the abdomen (keep about two finger-widths clear of the navel), as the tesamorelin prescribing information specifies. Disinfect the site, pinch a skin fold, insert at 90 degrees (45 degrees with little fat under the skin), rotate the spot on the abdomen every time.

What the research shows

The GHRH-analog pharmacology is studied in healthy people (Ionescu & Frohman, 2006). Tesamorelin is clinically documented for reducing visceral fat (details in the tesamorelin entry). For the fixed mix there is no separate study, the benefit derives from the individual compounds.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Visceral belly fat at 26 weeks23

Mean change in percent, by CT in people with HIV, tesamorelin alone

Phase 3 trial 12 412 participants
Placebo +5.0%
Tesamorelin alone -15.2%
Phase 3 trial 23 404 participants
Placebo -0.6%
Tesamorelin alone -10.9%

Values from the abstracts, studies with tesamorelin alone, not with the blend. IGF-1 rose by 81 percent in trial 1.

Normal liver fat after 12 months4

Share with less than 5 percent fat in the liver, 61 people with HIV and fatty liver

Liver fat below 5%4
Placebo 4%
Tesamorelin alone 35%

Liver fat fell by a relative 37 percent more than on placebo. Fasting glucose and HbA1c did not differ after 12 months.

Time to the first tolerated meal7

Median in hours after bowel surgery, phase 2, ipamorelin alone into a vein

Hours to the meal7
Placebo 32.6%
Ipamorelin alone 25.3%

The difference was not significant (p = 0.15). The trial tested ipamorelin for bowel paralysis, not as a growth hormone peptide.

Two-lobed glass gland on a stalk, circled by light trails that lead to a yellowish lobule of fat cells
Studies exist only on the components. Symbolic image.

Research status

Where the research stands

There is no study on the blend. Shown are registered trials on the single components: tesamorelin up to phase 3, ipamorelin up to phase 2. As of 26 Oct 2026. 11

  1. Preclinical Ipamorelin in cells, rats and pigs
  2. Phase 1 2 trials on components, 2 completed
  3. Phase 2 5 trials on components, 4 completed
  4. Phase 3 2 trials on components, 2 completed
  5. Approval not yet
675 participants in phase 3 Tesamorelin has been approved in the US since 2010, only for belly fat in HIV with lipodystrophy. ChEMBL lists ipamorelin with phase 2 as the highest phase. The blend has no approval and no study.13
Show all 8 trials on a timelineHide timeline 7 completed 1 running 4 with results
Phase 2
Phase 3
Without phase

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 2 trials on safety and pharmacokinetics, not shown as bars.

Side effects

  • Water retention, tingling, joint stiffness at higher GH levels.
  • Local reactions at the injection site.

Tolerability

Side effects of tesamorelin in phase 3

Out of 100 participants, how many had the event. Data on tesamorelin alone, 543 on the drug, 263 on placebo. There are no data on the blend.

6 of 100 Placebo
17 of 100 Tesamorelin alone
Event PlaceboTesamorelin alone
Injection-site reaction9 6%17%
Joint pain9 11%13%
Muscle pain9 2%6%
Fluid retention in legs or arms9 2%6%
Tingling (paraesthesia)9 2%5%
HbA1c of 6.5% or more9 1%5%

Ipamorelin alone: after bowel surgery 87.5 percent had a side effect against 94.8 percent on placebo. Almost everyone has complaints after abdominal surgery, which cannot be transferred to injection under the skin.97

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency. The bacteriostatic water brings a preservative.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same receptors, blends with Tesa + Ipa Blend or a different path: all in the TPD lexicon.

Tesa + Ipa Blend
Tesamorelin Component: GHRH analogue, approved in the US Ipamorelin Component: selective ghrelin mimetic CP10 (CJC + IPA) Same idea with CJC-1295 instead of tesamorelin CJC-1295 without DAC GHRH analogue, short-acting CJC-1295 with DAC GHRH analogue with albumin anchor Sermorelin Unmodified GHRH fragment GHRP-2 Ghrelin receptor, also raises cortisol HGH 191AA (Somatropin) Growth hormone directly instead of via the pituitary

FAQ

Common questions about Tesa + Ipa Blend

Short answers, each backed by the sources below.

What is in the Tesa + Ipa Blend?

Two peptides in one vial. Tesamorelin is the 44 building blocks of human GHRH with a protecting group. Ipamorelin is a peptide of five building blocks that acts on the ghrelin receptor. Both are in the lexicon on their own as well.95

Why two peptides together?

Because they act on the same release via two receptors. In 18 healthy men GHRH and the older ghrelin mimetic GHRP-6 together released more growth hormone than the sum of both alone. This has not been tested with tesamorelin and ipamorelin.8

What do the tesamorelin studies show?

In two phase 3 trials in people with HIV visceral belly fat fell by 15.2 and 10.9 percent in 26 weeks while subcutaneous fat stayed largely the same. In a fatty liver study 35 percent had normal liver fat after twelve months, 4 percent on placebo.234

What is known about ipamorelin?

In healthy men ipamorelin triggered a single GH pulse with a half-life of 2 hours. In animal studies it did not raise ACTH and cortisol more than GHRH, unlike GHRP-6 and GHRP-2. Clinically it only reached phase 2 after bowel surgery.657

Is the blend approved?

No. Tesamorelin alone has been approved in the US since 2010, only for excess belly fat in HIV with lipodystrophy. Ipamorelin is not approved anywhere. There is no registered trial on the ready-made blend.121310

Which side effects are known?

No data on the blend. On tesamorelin injection-site reactions, joint and muscle pain and fluid retention were more common than on placebo. In 5 percent long-term blood sugar (HbA1c) rose into the diabetes range, 1 percent on placebo.9

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Ghrelin receptor
The docking site for the hunger hormone ghrelin. In the pituitary it triggers growth hormone release.
GHRH
Growth hormone-releasing hormone from the brain. It signals the pituitary to release growth hormone.
GHRP
Growth hormone-releasing peptides. They act via the ghrelin receptor, a different path from GHRH.
HbA1c
Long-term blood sugar value over the past two to three months. From 6.5 percent it counts as diabetes.
IGF-1
A growth factor from the liver that growth hormone stimulates. A common measure of the effect.
Lipodystrophy
A disturbed distribution of body fat, for example with older HIV drugs and more belly fat.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
Subcutaneous
Into the fat layer just under the skin.
Visceral fat
Fat inside the abdomen around the organs, not directly under the skin. It is considered unfavourable for metabolism and heart.

Evidence

Sources

Show all 13 sourcesHide sources 8 Studies2 Trial registry3 Database checked 26 Oct 2026

Studies

  1. GH pulses under CJC-1295 (CJC-1295 with DAC was tested, not a component of the blend)

    Ionescu und Frohman, Journal of Clinical Endocrinology & Metabolism, 2006

    DOI 10.1210/jc.2006-1702 PMID 17018654
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Tesamorelin: phase 3 trial 1 on belly fat in HIV

    Falutz et al., New England Journal of Medicine, 2007

    DOI 10.1056/NEJMoa072375 PMID 18057338 NCT00123253
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Tesamorelin: phase 3 trial 2 with extension

    Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010

    DOI 10.1097/QAI.0b013e3181cbdaff PMID 20101189 NCT00608023
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Tesamorelin: study on fatty liver in HIV

    Stanley et al., The Lancet HIV, 2019

    DOI 10.1016/S2352-3018(19)30338-8 PMID 31611038 NCT02196831
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Ipamorelin: discovery and pharmacology (cells, rats, pigs)

    Raun et al., European Journal of Endocrinology, 1998

    DOI 10.1530/eje.0.1390552 PMID 9849822
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Ipamorelin: uptake, clearance and GH response in healthy men

    Gobburu et al., Pharmaceutical Research, 1999

    DOI 10.1023/A:1018955126402 PMID 10496658
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Ipamorelin: phase 2 trial after bowel surgery

    Beck et al., International Journal of Colorectal Disease, 2014

    DOI 10.1007/s00384-014-2030-8 PMID 25331030 NCT00672074
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. GHRH and a ghrelin mimetic amplify each other (healthy men)

    Bowers et al., Journal of Clinical Endocrinology & Metabolism, 1990

    DOI 10.1210/jcem-70-4-975 PMID 2108187
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Registry search for both together (0 results)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. Trials on the components on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. US prescribing information for tesamorelin

    DailyMed, U.S. National Library of Medicine

    Checked 26 Oct 2026 via DailyMed
  2. Tesamorelin in ChEMBL (approved 2010)

    ChEMBL, EMBL-EBI (CHEMBL1237026)

    Checked 26 Oct 2026 via ChEMBL
  3. Ipamorelin in ChEMBL (highest phase 2)

    ChEMBL, EMBL-EBI (CHEMBL58547)

    Checked 26 Oct 2026 via ChEMBL

In the shop

Tesa + Ipa Blend in the catalog

Sizes, prices and shipping times are on the product page.

To the product